-
Today Rongchang bio-anti-HER2 antibody association drugs are to be included in the breakthrough treatment varieties
Time of Update: 2021-01-15
Rongchang Bio plans to submit to China's State Drug Administration in the first half of 2021 vidicido single anti-treatment of urethra skin cancer new drug market applications.
-
Applications for Phase 3 clinical trials of Deki Pharmaceutical SVd combination therapy for rrMM were accepted by NMPA
Time of Update: 2021-01-15
output inhibitor (SINE) of its kind and the first and only FDA-approved drug for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Deqi Pharmaceuticals has conducted a Phase 2 registered clinical trial (code-named MARCH
-
Lingbei: The milestone in the development of new drugs stems from a humanized corporate culture
Time of Update: 2021-01-15
job of resource arrangements to seize the opportunities in the Chinese market. based on its research and development experience and market base in China, Lingbei will continue to work with the government and local partners to continuously provide
-
Improving cognitive indicators in AD patients Innovative oral therapy reaches the main clinical endpoint of phase 2b/3
Time of Update: 2021-01-15
The three studies clearly show that targeting congenital immune systems, including macrophages/small glial cells and fat cells, is an effective strategy for treating neurodegenerative diseases by inhibiting tyrosine kinases like mastatin.
-
AstraZeneta/13 ADC drug Enhertu is eligible for conditional approval in the European Union
Time of Update: 2021-01-15
December 2019, the drug was approved by the FDA to treat adult patients with non-removable or metastasis HER2-positive breast cancer who had received at least two or more anti-HER2 therapies, known as Enhertu.
-
First one-day advanced prostate cancer drug approved by FDA!
Time of Update: 2021-01-15
previously been given priority review, is the first and only oral gonogen-releasing hormone (GnRH) agent to treat advanced prostate cancer. approval is based on data on the effectiveness and safety of orGOVYX's Phase 3 HERO study of patients
-
AstraZeneia PARP inhibitors are to be included in the priority review and two new drugs have been approved clinically
Time of Update: 2021-01-15
, and the first approved PARP inhibitor. target DNA damage repair response (DDR) path, using the principle of "synthetic death" to kill cancer cells without affecting healthy cells. the drug was first approved in the U.S. in December 2014 to treat
-
And yellow medicine second treatment of advanced non-pancreatic neuroendocrine tumor new drug approved in sight
Time of Update: 2021-01-15
, Sovantini's application for adaptation to the treatment of advanced non-pancreatic neuroendocrine tumors is based on data from clinical studies SANET-ep.
-
The combined chemotherapy of SABCS-Mershaton K drug treated with three-yin breast cancer was better than that of Roche's T-drug combination
Time of Update: 2021-01-15
reduced the risk of disease development or death by 67 percent in previously untreated metastasis triple-negative breast cancer patients, who had a combined positive score (CPS) of at least 10 for PD-L1, a biomarker of tumor expression
-
The 2020 National Health Care Drug Negotiations Directory was officially released
Time of Update: 2021-01-15
Security (the Bureau): In order to implement the Opinions on Deepening the Reform of the Medical Security System issued by the Central Committee of the Communist Party of China and the State Council, in accordance with the Interim Measures
-
I just want to ask, can a medical representative do it for the rest of his life? Multiple MNC questions on behalf of the soul
Time of Update: 2021-01-15
much more mature than his actual age, and in his five years in the industry, the industry is no more special than any other industry. about getting a raise, changing jobs, and planning your career path is far more important than focusing
-
Beijing Ted Pharmaceutical imitation of class 4 benzene shun aku ammonium injection into the administrative approval stage
Time of Update: 2021-01-15
/> In the first half of 2020, China's public medical institutions terminal benzene Shun Aquku ammonium injection manufacturers competitive pattern, Hengrui Pharmaceutical dominance is difficult to shake, the exclusive market share of more than 70%, shanghai
-
And Platinum Pharmaceuticals jointly announced the launch of AbbVie's new Coronary Antibody Phase 1 clinical trial
Time of Update: 2021-01-15
Phase I clinical trials will be a randomized, double-blind, placebo-controlled study designed to assess the safety, pharmacodynamics, and pharmacodynamics of ABBV-47D11 in a single dose climb in COVID-19 adult hospitalized populations.
-
The collection of Chinese medicine is coming
Time of Update: 2021-01-15
is the current quality of Traditional Chinese medicine there are major problems. 2: Production process management. the multi-component effect of traditional Chinese medicine will inevitably make production quality control and process change difficult
-
Hundred-time Meishi Guibao: lose the pawn car or negative injustice?
Time of Update: 2021-01-15
On the 20th, the Ministry of Science and Technology imposed administrative penalties on Shishi Shiguibao (China) Investment Co., Ltd. (referred to below as Shi Guibao) and Ai Enkang Clinical Medical Research (Beijing) (referred to below as Ai Enkang
-
Ted Pharmaceuticals Chairman Zheng Xiangling was named the 2020 Pharmaceutical Industry Pioneer of the Year Ted Pharmaceuticals was named the best employer in the pharmaceutical industry in 2020
Time of Update: 2021-01-15
Among them, Ted Pharmaceuticals Chairman Zheng Xiangling was named the 2020 Pharmaceutical Industry Pioneer of the Year, Ted Pharmaceuticals was named the best employer in the pharmaceutical industry in 2020.
-
AstraZenecon has submitted a clinical application for a new generation of oral estrogen-influenced antagonists
Time of Update: 2021-01-15
AZD9833 belongs to a new generation of oral selective estrogen inhibitors (ER alpha) antagonists and degradation agents (SERDs).
-
2020 Karelli Pearl Single Resistance Summary Report
Time of Update: 2021-01-15
November, professor Wang Jie led the PASSION study, published in Journal of Thoracic Oncology, which provides new evidence of immune co-targeting (Carelli's beadone and apatinib) for the second-line treatment of broad-stage small cell lung cancer5.
-
Heavy Drug Discovery II - Engele Net
Time of Update: 2021-01-15
This is a chronic comprehensive disease caused by absolute or relative insulin deficiency, or decreased sensitivity of target cells to insulin, in which type 2 diabetes occurs as a result of a joint effect of insulin resistance and β cellular
-
Novaral JAK inhibitor Jakavi treats hospitalized COVID-19 patients with Phase III clinical failure!
Time of Update: 2021-01-15
On December 14, Novartis announced that phase III clinical trials (RUXCOVID) for the treatment of new coronavirus pneumonia (COVID-19) hospitalized patients with oral JAK1/2 inhibitor Ruxolitinib (Jakafi/Jakavi) Joint Standard Care (SoC) had not reached the primary endpoint.
